HCC

1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
TACEPhase 21 trial
Active Trials
NCT03817736Completed33Est. Jul 2023
P
PhilipsNetherlands - Amsterdam
1 program
Double Low-Dose protocol CTN/A1 trial
Active Trials
NCT03045445Completed68Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.TACE
PhilipsDouble Low-Dose protocol CT

Clinical Trials (2)

Total enrollment: 101 patients across 2 trials

Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy

Start: Mar 2019Est. completion: Jul 202333 patients
Phase 2Completed
NCT03045445PhilipsDouble Low-Dose protocol CT

"Double Low-Dose" DECT for HCC Imaging

Start: May 2017Est. completion: Sep 201968 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space